Rhythm treats rare genetic obesity disorders.
Rhythm Pharmaceuticals, Inc. (RYTM) is expected to report earnings on Tuesday, November 3, 2026, before the open. Estimated release time 07:17 ET. Consensus EPS estimate is $-0.71.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-04 | Jun 2026 qtr | $-0.81 | $-0.73 | +9.6% | $71.25M |
| 2026-05-05 | Mar 2026 qtr | $-0.86 | $-0.83 | +3.5% | $60.11M |
| 2026-02-26 | Dec 2025 qtr | $-0.79 | $-0.73 | +7.6% | $57.25M |
| 2025-11-04 | Sep 2025 qtr | $-0.72 | $-0.82 | -13.9% | $51.30M |
| 2025-08-05 | Jun 2025 qtr | $-0.66 | $-0.75 | -13.6% | $48.50M |
| 2025-05-07 | Mar 2025 qtr | $-0.69 | $-0.81 | — | $32.70M |
| 2025-02-28 | Dec 2024 qtr | $-0.69 | $-0.72 | -4.3% | $41.83M |
| 2024-11-06 | Sep 2024 qtr | $-0.80 | $-0.71 | +11.3% | $33.25M |
RYTM has beaten consensus EPS in 4 of its last 7 scored quarters.
See RYTM on the live calendar →